Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
Institute for Clinical and Experimental Medicine
Institute for Clinical and Experimental Medicine
Nakhon Phanom Hospital
Instituto Nacional de Cancer, Brazil
Norwegian Institute of Public Health
Manchester University NHS Foundation Trust
Instituto Nacional del Cáncer, Argentina
Turku University Hospital
Tata Memorial Hospital
Norwegian Department of Health and Social Affairs
East and North Hertfordshire NHS Trust